ReviewBreast cancer research : BCR2011
Minimal residual disease and circulating tumor cells in breast cancer.
Review in Breast cancer research : BCR, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 60 citations in OpenAlex.
- Trial
- Mitochondrial transcript abundance in breast cancer circulating tumour cells may reflect both blood-derived transcripts and biological heterogeneity.Clinical & experimental metastasis · 2026Article
- Circulating Tumour Cells as Potential Biomarkers for Oral Squamous Cell Carcinoma.Molecules (Basel, Switzerland) · 2026Review
- Circulating tumor DNA detection of local recurrence in a patient with early stage triple-negative breast cancer.Breast cancer research and treatment · 2025Article
- Microfluidic isolation and release of live disseminated breast tumor cells in bone marrow.PloS one · 2025Article
- Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction.EMBO molecular medicine · 2024Article
- Isolation, Detection and Analysis of Circulating Tumour Cells: A Nanotechnological Bioscope.Pharmaceutics · 2023Review
- Marker-free characterization of full-length transcriptomes of single live circulating tumor cells.Genome research · 2023Article
- Functional Genomic Analysis of Breast Cancer Metastasis: Implications for Diagnosis and Therapy.Cancers · 2021Review
- Detection of Minimal Residual Disease in the Peripheral Blood of Breast Cancer Patients, with a Multi Marker (MGB-1, MGB-2, CK-19 and NY-BR-1) Assay.Breast cancer (Dove Medical Press) · 2021Article
- Article
- Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents.Cancer discovery · 2019Article
- Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management.Biological research · 2018Review
- Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation.Small (Weinheim an der Bergstrasse, Germany) · 2018Article
- Next generation ligand binding assays-review of emerging real-time measurement technologies.The AAPS journal · 2014Review
- International study on inter-reader variability for circulating tumor cells in breast cancer.Breast cancer research : BCR · 2014Article
- Cytokeratin-based CTC counting unrelated to clinical follow up.Journal of thoracic disease · 2013Article
- Luminal breast cancer: from biology to treatment.Nature reviews. Clinical oncology · 2013Review
- Heterogeneity of ERα and ErbB2 Status in Cell Lines and Circulating Tumor Cells of Metastatic Breast Cancer Patients.Translational oncology · 2012Article
- Circulating tumor cell isolation, culture, and downstream molecular analysis.Biotechnology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor cell dissemination in bone marrow or other organs is thought to represent an important step in the metastatic process. The detection of bone marrow disseminated tumor cells is associated with worse outcome in early breast cancer. Moreover, the detection of peripheral blood circulating tumor cells is an adverse prognostic factor in metastatic breast cancer, and emerging data suggest that this is also true for early disease. Beyond enumeration, the characterization of these cells has the potential to improve risk assessment, treatment selection and monitoring, and the development of novel therapeutic agents, and to advance our understanding of the biology of metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.